| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| R&D Expense | $42.6M | +34.5% |
| SG&A Expense | $21.9M | +25.6% |
| Operating Income | -$64.5M | -31.3% |
| Pre-tax Income | $57.4M | +28.7% |
| Net Income | -$57.4M | -28.8% |
| EPS (Basic) | -$1.34 | +38.2% |
| EPS (Diluted) | -$1.34 | +38.2% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Cash & Equivalents | $49.7M | -69.5% |
| Short-term Investments | $105.9M | +1313.1% |
| Current Assets | $159.5M | -7.3% |
| Total Assets | $209.5M | +15.4% |
| Current Liabilities | $10.9M | -0.2% |
| Total Liabilities | $13.1M | -8.8% |
| Stockholders' Equity | $196.4M | +17.5% |
| Line Item | 2025-12-31 | Y/Y |
|---|---|---|
| Operating Cash Flow | -$56.4M | -57.4% |
| Capital Expenditures | $94K | +49.2% |
| Investing Cash Flow | -$139.5M | -828.2% |
| Financing Cash Flow | $82.7M | -40.9% |
| Free Cash Flow | -$56.5M | -57.4% |